← Signal Board

Verrica Pharmaceuticals financial statements

베리카 파머슈티컬스NASDAQ:VRCA · Nasdaq · Healthcare · sector #17
$4.14-1.66%
2026-10-07 close

Verrica Pharmaceuticals's published financial data is dated 2026-10-04. 2024 revenue was $8M. 2024 operating profit was −$66M.

Reported results

Financial safety

Reference indicatorAs of 2024
Distress zoneFinancial-metric reference signal
Altman Z'' zoneZ'' -24.15
Distress
Grey
Safe
The marker shows the current Z'' value within the displayed zones.
Altman Z''
-24.15
Beneish M-Score
-4.33

No statistical flag

Sloan accrual
-28.91%

부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.

Factual information, not investment advice.

Earnings quality · Piotroski F-Score

2/9Weak

Piotroski measures year-over-year financial improvement, not absolute quality.

Financial improvement score2/9

Profitability

  • Positive ROANot passed
  • Positive OCFNot passed
  • Improving ΔROANot passed
  • Accruals (OCF > net income)Pass

Leverage & liquidity

  • Lower debtNot passed
  • Higher current ratioNot passed
  • No new sharesNot passed

Efficiency

  • Higher gross marginNot passed
  • Higher asset turnoverPass

Calculation note: F7(신주)은 equity/asset 유지로 근사

Already-stable companies may score lower when year-over-year improvement is limited.

Factual information, not investment advice.

Forensic signals

Anomaly and structural signals observed in the financial statements.

Revenue qualityDanger

매출 흑자인데 영업CF 적자 (OCF/매출 -805%). 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Balance sheetDanger

자본잠식 — 자본총계가 마이너스입니다. 부실 위험을 나타내는 사실 지표입니다.

Factual information, not investment advice.

Risk sensitivity — adverse assumptions

Metric changes under stated assumptions; not a forecast or investment advice.

Base metrics

Operating margin
-871.3%
Interest coverage
-7x
Return on equity (ROE)
—

Operating margin −5pp

Operating loss
Interest coverageBase -7x adverse case -7x
Return on equity (ROE)Base — adverse case —

Revenue −15%

Interest coverage risk
Interest coverageBase -7x adverse case -6x
Return on equity (ROE)Base — adverse case —

Interest rate +2pp

Interest coverage risk
Interest coverageBase -7x adverse case -6.2x
Return on equity (ROE)Base — adverse case —

Interest coverage limit

Already below the limit by 995.7pp

Interest coverage limit at an operating margin of 124.4%

Interest expense coverage threshold

Verrica Pharmaceuticals notifications

Quantus Signal · live data · not investment advice · Privacy Policy